文献速递胰腺与胆道疾病消化内镜

美国高级内镜医生ERCP术后胰腺炎预防实践模式调查

Practice patterns of post-ERCP pancreatitis prophylaxis techniques in the United States: a survey of advanced endoscopists.
PubMed 文献 · Gastrointest Endosc · 2019-11-16

该调查向233名参与高级内镜 fellowship 项目的美国内镜医生发放匿名在线问卷,62人回复(26.7%)。受访者中直肠NSAIDs用于PEP预防比PPS更常见,但仅40.1%的受访者将直肠NSAIDs用于平均风险患者。

要点

  • 直肠NSAIDs用于PEP预防比PPS更常用。
  • 仅40.1%受访者对平均风险患者使用直肠NSAIDs。
  • 83.0%受访者使用快速静脉补液预防PEP。

核心结论

  • 在美国参与高级内镜 fellowship 项目的前列腺内镜医生中,直肠NSAIDs用于预防PEP比PPS更频繁。
  • 尽管证据支持对平均风险患者使用直肠NSAIDs预防PEP,但本调查中不到一半的受访者报告了该实践。

研究设计与样本

  • 匿名在线16项问卷调查,发送给233名参与高级内镜 fellowship 项目的 advanced endoscopists。
  • 62名内镜医生回复,回复率26.7%。

主要发现

  • 大多数受访者在三级转诊中心工作(57/60,95.0%),实施ERCP超过5年(44/59,74.6%)。
  • 所有受访者(60/60,100.0%)报告与 fellows 一起工作。
  • 多数PPS使用者(41/57,72.0%)仅在高风险患者中使用PPS,且在≤25%的ERCP中使用PPS(38/59,64.4%)。
  • 多数受访者仅在高风险患者中使用直肠NSAIDs(34/57,59.7%),而40.1%(23/57)的受访者在平均风险患者中使用直肠NSAIDs预防PEP。
  • 多数受访者(49/59,83.0%)报告使用快速静脉补液预防PEP。

关键数值与推荐

  • ASGE推荐在高风险个体中放置预防性胰管支架(PPS)和使用直肠NSAIDs以降低PEP发生率和严重程度,并建议直肠吲哚美辛可能降低平均风险个体PEP风险和严重程度。
  • ESGE推荐所有接受ERCP的患者使用直肠吲哚美辛。

临床怎么用

  • 调查反映美国高级内镜医生中直肠NSAIDs用于PEP预防比PPS更常见,但平均风险患者中直肠NSAIDs使用不足。
  • 快速静脉补液是常用的PEP预防措施之一。

局限性

  • 回复率仅26.7%(62/233),可能存在无应答偏倚。
  • 调查基于自我报告,可能与实际实践存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The American Society for Gastrointestinal Endoscopy recommends prophylactic pancreatic duct stent placement (PPS) and rectal nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce the incidence and severity of post-ERCP pancreatitis (PEP) in high-risk individuals and suggests that rectal indomethacin may decrease the risk and severity of PEP in average-risk individuals. The European Society for Gastrointestinal Endoscopy recommends rectal indomethacin for all patients undergoing ERCP. Previous surveys of European endoscopists revealed low adoption of PPS or rectal NSAIDs to prevent PEP. We sought to capture current practice in the prevention of PEP among endoscopists in the United States involved in advanced endoscopy fellowship programs. METHODS: An anonymous online 16-item survey was e-mailed to 233 advanced endoscopists involved in advanced endoscopy fellowship programs. RESULTS: Of the 233 endoscopists who were invited to participate, 62 responded (26.7%). Most respondents reported working in tertiary referral centers (57; 95.0%) and performing ERCP for greater than 5 years (44; 74.6%). All respondents (60; 100.0%) reported working with fellows. Most PPS users (41; 72.0%) reported use of PPS in high-risk patients only and using PPS for PEP in ≤25% of ERCPs (38; 64.4%). Most respondents reported using rectal NSAIDs for high-risk patients only (34; 59.7%) compared with respondents (23; 40.1%) who reported using rectal NSAIDs for prevention of PEP in average-risk patients undergoing ERCP. Most respondents (49; 83.0%) also reported using rapid intravenous fluids to prevent PEP. CONCLUSIONS: Among endoscopists involved in advanced endoscopy fellowships in the United States, rectal NSAIDs are used more frequently than PPS in the prevention of PEP. Despite mounting evidence supporting the use of rectal NSAIDs to prevent PEP in average-risk patients, less than half of the respondents in this survey reported such practice.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Avila P, Holmes I, Kouanda A, et al. Practice patterns of post-ERCP pancreatitis prophylaxis techniques in the United States: a survey of advanced endoscopists. Gastrointest Endosc. 2019. PMID: 31743690. doi:10.1016/j.gie.2019.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。